Anti-CD38 Therapy Administration in Multiple Myeloma

Tanika Pittman, APRN, and Jill Burke, NP, discuss practical considerations surrounding the selection and administration of anti-CD38 antibody-based therapies for patients with multiple myeloma, focusing on how clinical trial evidence translates into real-world treatment delivery. Tanika emphasizes incorporating treatment logistics and patient experience into counseling, including IV administration time, infusion-related reactions, premedications, observation requirements, IV access, staffing, and scheduling. The faculty discuss how subcutaneous administration can reduce time in the clinic and influence workflow, while emphasizing that patients still require education regarding administration-related reactions, infection risk, and when to contact the care team. They also highlight the importance of aligning nursing, pharmacy, APPs, and other providers around standardized workflows and setting realistic expectations regarding laboratory and pharmacy processes. Jill describes how transitioning appropriate patients from IV to subcutaneous administration may improve convenience and independence, allowing patients with multiple myeloma to spend less time in clinic and resume activities such as travel. Tanika further notes that newer delivery technologies, including on-body administration options for isatuximab, may reduce administration time, while stressing that successful implementation requires broader workflow adjustments rather than simply changing the route of administration.